Learn About Ewing Sarcoma

What is the definition of Ewing Sarcoma?

Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.

What are the causes of Ewing Sarcoma?

The most common mutation that causes Ewing sarcoma involves two genes, the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. A rearrangement (translocation) of genetic material between chromosomes 22 and 11, written as t(11;22), fuses part of the EWSR1 gene with part of the FLI1 gene, creating the EWSR1/FLI1 fusion gene. This mutation is acquired during a person's lifetime and is present only in tumor cells. This type of genetic change, called a somatic mutation, is not inherited.

How prevalent is Ewing Sarcoma?

Approximately 3 per 1 million children each year are diagnosed with a Ewing sarcoma. It is estimated that, in the United States, 250 children are diagnosed with one of these types of tumor each year. Ewing sarcoma accounts for about 1.5 percent of all childhood cancers, and it is the second most common type of bone tumor in children (the most common type of bone cancer is called osteosarcoma).

Is Ewing Sarcoma an inherited disorder?

This condition is generally not inherited but arises from a mutation in the body's cells that occurs after conception. This alteration is called a somatic mutation.

Who are the top Ewing Sarcoma Local Doctors?
Pediatric Hematology Oncology | Hematology | Oncology
Pediatric Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Lars Wagner is a Pediatric Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Wagner and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration. Dr. Wagner is currently accepting new patients.

Mitchell Cairo
Hematology | Oncology
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
Languages Spoken:
English

Mitchell Cairo is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Cairo and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Burkitt Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Albert Schweitzer Str. 33, 
Muenster, NW, DE 

Uta Dirksen practices in Muenster, Germany. Dirksen and is rated as an Elite expert by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Osteotomy, and Bone Marrow Transplant.

What are the latest Ewing Sarcoma Clinical Trials?
Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Background: The drug PEN-866 can remain in tumor cells longer than it does in normal cells. It also may be more effective than other drugs at treating Ewing sarcoma and rhabdomyosarcoma. Researchers want to learn if combining PEN-866 with other drugs can treat certain cancers in adolescents and young adults.

Match to trials
Find the right clinical trials for you in under a minute
Get started
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Summary: Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Who are the sources who wrote this article ?

Published Date: June 01, 2016
Published By: National Institutes of Health